The predominant benefit in terms of the combined endpoint was powered by a 24% reduction in the rate of adjudicated (first) hospitalizations for worsening HF as a first event in those receiving valsartan versus placebo (13.8% vs. 18.2% p 0.001). The other primary endpoint of all-cause ...
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such...
We compare the differences between groups (ASCVD: low + borderline + intermediate versus high-risk group; SCORE2/SCORE2-OP: low + moderate versus high + very high-risk group and SCORE2-Diabetes: low + moderate versus high + very high-risk group) in terms of change from baseline in body...
(4 ± 2% vs. 4 ± 3% vs. 4 ± 2%;p= 0.29). Furthermore, the groups were not statistically different in terms of self-reported rates of diabetes, coronary artery disease, chronic heart failure, COPD and chronic kidney disease. Only self-reported levels of arterial hypertension showed a ...